NEW YORK (AP) – Drugmaker Pfizer Inc. said that early results from a late-stage study of its pain treatment Lyrica showed that it did better than a placebo in reducing one type of pain after a spinal cord injury.
The world’s largest drugmaker said the study involved 220 subjects from 10 countries, and it will conduct more analysis of the results.
The pain, known as central neuropathic pain, is caused by a lesion in the central nervous system and frequently occurs after a spinal cord injury, the New York drugmaker said.
Lyrica is approved in the United States to treat diabetic nerve pain, shingles-related pain, fibromyalgia and seizures in some adult epilepsy patients.
Date: June 21, 2011
Source: Associated Press
Filed Under: Drug Discovery
